[New oral hypoglycemic drugs in diabetic kidney disease].
New antidiabetic drugs let optimize the treatment of diabetes. In clinical practice the use of glitazone, incretin drugs (including GLP-1 receptor agonists and DPP-4 dipeptidyl peptidase inhibitors) or glucose-2-cotransporter (SGLT-2) inhibitors is increased. The potential use of these drugs in patients with renal insufficiency is limited both to impaired renal function (and the associated risk of drug or metabolite accumulation in the body), and due to limited clinical data assessing the safety of their use in this group of patients. However, previous experience has allowed us to formulate recommendations for the use of some of the new antidiabetic agents in patients with renal impairment. This provides an opportunity to improve the management of diabetes mellitus and to reduce the complications associated with diabetes (especially cardiovascular disease) in diabetic patients with renal disease.